



Darier disease: first molecular study of a Portuguese family

Andreia Almeida^a, Maria de Lurdes Lobo^b, Cecília Moura^c, Isabel Rivera^{a,d,*}

^a Metabolism & Genetics Group, Research Institute for Medicines (iMed.Ulisboa), Faculty of Pharmacy, University of Lisbon, Portugal

^b Centro Hospitalar Universitário de Lisboa Central, Portugal

^c Department of Dermatology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Portugal

^d Departments of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon, Portugal



ARTICLE INFO

Keywords:

Genetics

Darier disease

ATP2A2

SERCA2

Mutational analysis

ABSTRACT

Background: Darier disease (DD) is a rare autosomal dominant condition characterized by skin lesions. Additionally, a wide range of neuropsychiatric symptoms is frequently reported in DD patients. This genodermatosis relies on mutations in the ATPase sarcoplasmic/endoplasmic reticulum Ca²⁺ transporting 2 (*ATP2A2*) gene, which encodes an ATPase responsible for pumping Ca²⁺ from the cytosol to the lumen of the ER.

Objective: Herein we studied the molecular aspect of a two-generation Portuguese family with DD history with clinical variability.

Methods: All exons and intron-exon borders of genomic *ATP2A2*, as well as coding *ATP2A2*, were sequenced. Relative levels of *SERCA2* mRNA and protein were quantified by qPCR and western blotting, respectively.

Results: The c.1287+1G > T variant was identified in all affected individuals, whereas the unaffected individual was shown to carry the wild-type *ATP2A2* sequence in both alleles. This variant leads to the skipping of full exon 10, which consequently generates a frameshift originating a premature STOP codon in exon 11 (p.V395 = fs*19). Although the mutant mRNA seems to partially escape degradation, results suggest synthesis inhibition or immediate degradation of the mutant protein. Neuropsychiatric and other occurrences affecting certain patients are also reported.

Conclusion: This is the first study of DD in Portugal, the variant identified, previously described in a single Japanese patient, may be considered a pathogenic mutation, and haploinsufficiency the mechanism underlying DD pathology in these patients. This study also highlights the co-occurrence of neuropsychiatric features in DD.

1. Introduction

Darier Disease (DD, OMIM #124200) is a rare autosomal dominant genodermatosis, with complete penetrance and variable expressivity. It is caused by heterozygous mutation in the ATPase sarcoplasmic/endoplasmic reticulum Ca²⁺ transporting 2 (*ATP2A2*) gene, which encodes the Sarco/Endoplasmic Reticulum Ca²⁺ ATPase 2 (*SERCA2*), responsible for pumping Ca²⁺ from cytosol to the lumen of the ER. According to Leiden Open Variation Database v3.0 (<http://www.lovd.nl/3.0/home>), 420 public variants have been reported in the *ATP2A2* gene, of which 295 are unique.

ATP2A2 is transcribed into 21 exons and alternative splicing of the pre-mRNA generates multiple isoforms [1, 2]. These isoforms vary in their tissue expression pattern: *SERCA2a* has been found to be restrained to cardiac slow-twitch muscle, skeletal and smooth muscle [3], whereas *SERCA2b* is the ubiquitous isoform, expressed in non-muscle cells,

including several areas of the brain [4], and highly expressed in the epidermis [1, 5].

At a molecular level, *ATP2A2* mutations lead to depletion of ER Ca²⁺ stores and ER stress, particularly in the skin [1]. Haploinsufficiency or dominant-negative effect have been the mechanisms postulated for DD pathology [6, 7, 8]. Histologically, acantholysis and dyskeratosis are the two major hallmarks observed in lesional epidermis [1]. Interestingly, both lesional and non-lesional DD keratinocytes appear to suffer ER Ca²⁺ depletion and ER stress, but only lesional keratinocytes exhibit changes in trafficking and maturation of desmosomal proteins [9, 10], suggesting the need for an interaction between secondary factors and the pathogenic variant.

DD runs a chronic and relapsing course after its onset, which usually occurs during the first or second decade of life, and may aggravate with age [3, 11]. Clinical manifestations include nail abnormalities and focal skin lesions, characterized as redish-brownish crusted keratotic papules,

* Corresponding author.

E-mail address: iarivera@ff.ulisboa.pt (I. Rivera).

<https://doi.org/10.1016/j.heliyon.2019.e02520>

Received 16 February 2019; Received in revised form 26 May 2019; Accepted 23 September 2019

2405-8440/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

distributed in seborrheic areas of the body [1]. Skin lesions can be exacerbated by environmental factors, such as UV-B radiation, and are more susceptible to infection by bacterial, fungal, and viral microorganisms [3].

Additionally, a range of neuropsychiatric features such as depression, suicidal behavior, bipolar disorder, schizophrenia, intellectual disability, epilepsy, cognitive deficit, mental retardation, and learning disability have been reported in DD patients [12, 13, 14, 15]. Gordon-Smith et al. have found higher lifetime prevalence rates of mood disorders (50%), especially major depression (30%) and epilepsy (3%), to be present within a sample of one hundred unrelated DD patients compared with that in the general population [16].

Current treatments used to manage DD lack efficacy and safety: oral or systemic retinoids are the most frequently prescribed drugs, which nevertheless harbor a large number of noxious side effects and cannot be prescribed to women of child-bearing age [17].

In this study we aim to describe the molecular aspects, the clinical features and the neuropsychiatric occurrences within this two-generation Portuguese family carrying Darier disease.

2. Materials and methods

2.1. Participants

Five individuals from a two-generation Portuguese family carrying Darier disease agreed to enroll in this study: four affected relatives and one unaffected relative. This study was approved by the local Ethics Committee, and written informed consents were obtained from each participant in this study. The dermatologists who follow-up the patients were informed about the study and gave their consent.

Data concerning the clinical manifestations and the neuropsychiatric features of the affected individuals were gathered by medical note assessment and interview.

2.2. PCR and RT-PCR amplification

Nucleic acids were extracted from whole blood peripheral lymphocytes, collected from each individual. All exons and flanking intronic boundaries of genomic *ATP2A2* were amplified by PCR using 17 sets of primers designed with Primer3 program (<http://primer3.ut.ee>) (Table 1). PCR conditions were the following: initial denaturation at 98 °C for 30 s; 35 cycles of 98 °C for 10 s; annealing at 55 °C or 58 °C for 10 s;

extension at 72 °C for 20 s; a final extension step for 5 min. Each PCR reaction was carried out in a total volume of 25 µL using the Phusion® High-Fidelity DNA Polymerase (New England Biolabs) protocol, and approximately 200 ng of genomic DNA. First strand cDNA was synthesized from total RNA (1 µg) using Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The entire coding region of *SERCA2b* cDNA was amplified by PCR using six overlapping sets of primers, specifically designed with Primer3 program (Table 1). Each PCR was performed according to protocol for Phusion® High-Fidelity DNA Polymerase, with annealing temperatures of 60 or 61 °C, a final MgCl₂ concentration of 1.5 mM or 3.0 mM, in a total volume of 25 µL. RT-PCR products were run on 2% agarose gels for detection of splicing errors.

2.3. Sequence analysis

PCR and RT-PCR products were purified from solution or directly from agarose gel, using Isolate II PCR and Gel Kit (Bioline). PCR forward and/or reverse primers were added to the purified products from each individual sample and submitted to bi-directional Sanger sequencing (GATC Biotech). All chromatograms corresponding to PCR and RT-PCR fragments were carefully analyzed using the BLAST program (NCBI).

2.4. Quantitative PCR

Quantitative PCR was performed using Maxima SYBR Green qPCR Master Mix (Thermo Fisher Scientific) and the CFX96 Touch™ Real-Time System (Bio-Rad). Two sets of primers were designed to amplify both mutant and wild-type transcripts (GGTGACAAGTTCCTGCTGA forward and AGTGTGCTTGATGACAGAGACA reverse), or the wild-type transcripts only (TGTGCTCTTTGTAATGACTCTGC forward and AGAAA-GACCCITCAATTCCGGTATCA reverse). The set of primers designed strictly for wild-type transcripts allows the amplification of exon 10, which is missing in mutant mRNA, while the set of primers for both wild-type and mutant anneals in exons 6 and 7. Target complementary DNA sequences were normalized to beta-actin.

2.5. Western blotting

Whole blood peripheral lymphocytes were homogenized and proteins were isolated using RIPA buffer (Pierce, Thermo Fisher Scientific), containing protease and phosphatase inhibitors (Thermo Fisher Scientific). An amount of 25 µg, evaluated by bicinchoninic acid method of total

Table 1

PCR and RT-PCR primers and related parameters for amplification of genomic and coding *ATP2A2*, respectively.

	Exon	Forward Primer	Reverse Primer	Product size (bp)	Annealing Temperature (°C)	
PCR amplification	1	gcaagaggaggaggaggaga	ccatcttccctggctctccc	307	58	
	2 + 3	cctccctctgacacattgct	agacacagcttgcaactcca	354		
	4	catgttggcaggttgctct	ccattgcactccagcctg	480		
	5	tgctctgtgtctgtgctct	tgacaggaaggagggtgcta	490		
	6	ctcatttcagccgccttt	aaggacagctgaggcaagag	202		
	7	ggtggcagatgaatgagaggt	agtgatggtggcagtgaaa	249		
	8	cagcgtcggtatattaagttggg	acaagaaccaacgacacgga	573		
	9	tgcttgcctttgctcaagct	tgccacaccagatcctttaa	225		
	10	ggggcgggaggaatcaatag	ctttcattccaccacccca	234		
	11	gacagattgtctttgtgga	gagagtaggacagctgcagaca	309		
	12 + 13	ttgccaccagtagtatcca	tgagggtgtggacaagaa	516		
	14	ggcaacaagcgaaact	gaggctactatgtgcttctg	478		
	15	tttccaagagacctacgg	tttctgtcttgcactccc	483		55
	16	ttttctggaggaggcg	aggcactctctgtctttgc	426		
	17 + 18	ccggtaccatactgtccc	tgactacacacaattccccgg	690		
	19 + 20	tactgccactgtgacacgtg	gaaatcccaatcggtgcatgc	449	58	
	21	tctagatgctaccctgtgtgg	tcagctcatgcacagggttgg	299		
	1–6	aagaggaggaggaggagac	ttcactctgagaaattgactgg	676		61
	6–8	tggtgacaagtctctgctg	tgacactgacactctggttg	629	60	
	8–13	gctctggaactcgagaat	accctactcgaatgacag	699		
	13–15	accacactcgagttggaag	gccacaatgtggagaagtt	659		
15–18	gtgaacgatgctctgctct	aaagtccgggtgtcctct	537			
17–20	ctgctgcatgggtgctcat	ttcagcagaaatagacagttgctt	663			

protein from each individual was mixed with Laemli loading buffer. Two sets of samples were studied as heated (95 °C for 5 min) and unheated samples, which were resolved in 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride membranes (GE Healthcare Life Sciences, Amersham Hybond) at 300 mA for 100 min at 4 °C. Blots were blocked with a solution containing 5% bovine serum albumin, TBS (1x), and 0.1% Tween® 20 for 1 h at room temperature, followed by incubation with rabbit polyclonal anti-SERCA2 (dilution 1:10000; #4388 Cell Signaling). Membranes were probed with anti-rabbit IgG secondary antibody (dilution 1:2000; #7074, Cell Signaling Technologies, Inc.), followed chemiluminescent detection with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific). SERCA2 expression was normalized to beta-actin (dilution 1:4000; Sigma-Aldrich).

2.6. Genotype-phenotype correlation

Sequenced exons and flanking intronic boundaries from *ATP2A2* were analyzed closely in search for genetic variants other than the pathogenic mutation. Additionally, *ATP2A2* and *SERCA2* expression levels were also considered for genotype-phenotype correlation.

3. Results

3.1. Clinical characterization of the DD patients

The pedigree structure of the two-generation family under study is depicted in Fig. 1. All affected family members were diagnosed by dermatopathology during their first decade of life. These individuals shared a monomorphic dermatosis, notably symmetrical, containing multiple non-follicular hyperkeratotic papules with 2–4 mm in diameter, brownish, rounded and occasionally crusted, on skin usually healthy or erythematous skin during periods of inflammatory exacerbation. The lesions were distributed along the entire lateral cervical region, anterior thorax and lower abdominal region (especially flanks), appearing also in the scalp, and predominant in retroauricular region. Palms of the hands presented multiple millimetric depressions filled by keratin (palmar pits). Nails of the hands and feet presented discrete longitudinal leukonychia, fragility, fissure and dyskeratosis with V-shaped notches on the distal end of the nail plate. Relapses of greater clinical severity usually led to skin eruptions or infections by bacterial agents. Patients' clinical course was in line with the worsening of the disease over the years. Moreover, patients agreed that skin lesions were exacerbated by sweat, friction, and sunlight, particularly during the summer.

However, the clinical severity of the disease varied from patient to patient. At the skin level, patient I.2 had more relapses than his brother (I.3) whereas patient II.1's relapses were more frequent and more severe than those of his father (I.2). In addition to their skin phenotype, viral, immunologic, and neuropsychiatric occurrences were mainly observed in the younger patients (II.1 and II.3) (Table 2).

To manage DD, the patients took medicines prescribed by dermatologists such emollients, topical antibiotics, and retinoids such as acitretin, a derivative of vitamin A. They also avoided being exposed to the sun during the summer in order to prevent focal lesions to emerge or exacerbate. Patients with other occurrences, referred in Table 2, took additional medicines to manage these.

3.2. Splice-site mutation in *ATP2A2* gene leads to exon skipping followed by frameshift and premature nonsense codon

In order to identify the pathogenic variant, we analyzed the genomic and messenger sequences of *ATP2A2* gene. Bi-directional Sanger sequence analysis of all exons and respective intronic boundaries revealed a substitution in the canonical splice donor site of the guanine (+1) for a thymine in intron 10 (c.1287+1G > T or IVS10+1G > T) (Fig. 2); no additional sequence alterations were detected in any




Fig. 1. Pedigree of the two-generation Portuguese family where Darier Disease segregates. The affected individuals are denoted by solid black symbols whereas unaffected individuals are denoted by open symbols. Arrows point to the individuals who participated in this study.

individual. Disruption of the mutant pre-mRNA splicing process was proposed by several public bioinformatic programs, namely Human Splicing Finder (<http://www.umd.be/HSF3/>) and NetGene2 (<http://www.cbs.dtu.dk/services/NetGene2>).

By analyzing RT-PCR products spanning exons 8 to 13 from *ATP2A2* gene, we confirmed that the splicing process is affected, leading to a shorter transcript (596 bp) in each affected relative (I.2, I.3, II.1 and II.3), whereas the unaffected relative (II.2) showed a normal RT-PCR fragment (699 bp) equivalent to two copies of the wild-type *ATP2A2* gene (Fig. 3a). Bi-directional sequence analysis of these RT-PCR products, whose normal and shorter fragments were directly purified from the gel, revealed the skipping of full exon 10 in the shorter transcript of each affected relative (Fig. 3b), whereas the normal fragment corresponded to the sequence derived from the wild-type *ATP2A2*. Therefore, all four patients were shown to carry the same mutation in heterozygosity, which, leading to the skipping of exon 10, consequently originates a frameshift, which putatively introduces a downstream premature stop codon (p.V395 = fs*19) in exon 11.

Furthermore, it was proved that the unaffected individual carries two normal alleles, what allowed us to use her as a control in subsequent analyses since she shares the same genetic background of all the patients.

3.3. Wild-type *SERCA2* mRNA expression is significantly decreased while mutant mRNA appears to partially escape Nonsense-Mediated mRNA Decay (NMD)

We decided to examine the expression levels of both wild-type and mutant *SERCA2* mRNA by quantitative PCR. Results revealed a reduction of approximately 50–55% of wild-type plus mutant *SERCA2* mRNA expression when compared to the healthy subject, whose expression was considered 100% (Fig. 4a). Relative expression levels of wild-type mRNA alone corresponded to approximately 36% in the patients, whereas the mutant mRNA expression corresponded to 18% (Fig. 4b). These findings were in agreement with what is seen in Fig. 3a, highly suggesting that a small amount of mutant *SERCA2* mRNA fails to be recognized by NMD, which could potentially lead to the generation of abnormal *SERCA2* protein.



3.4. Wild-type *SERCA2* is significantly reduced whereas mutant *SERCA2* is not detected

If translated, the mutant *SERCA2* mRNA would originate an abnormal

Table 2

Additional information about participants' actual age, age of onset, and other phenotypic manifestations.

Individuals	Actual Age	Age of DD onset	Cutaneous phenotype	Neuropsychiatric co-occurrences	Other occurrences
I.2	56	1 st decade of life, around six years old	++	None	Herpes simplex virus in the left eye
I.3	61		+	None	None
II.1	31		+++	Single suicide attempt Depressive moods	Membranous glomerulonephritis Left ear deafness Chronic left middle ear infection
II.3	34		+	Epilepsy	Leukemia
II.2	24	-	-	None	None

**Fig. 2.** Identification of ATPase sarcoplasmic/endoplasmic reticulum Ca^{2+} transporting 2 (*ATP2A2*) pathogenic mutation. Sanger sequencing of the *ATP2A2* gene revealed the transversion c.1287+1G > T or IVS10+1G > T in intron 10.**Fig. 3.** The IVS10+1G > T variant leads to full skipping of exon 10. (a) Agarose gel electrophoresis of RT-PCR products, spanning exons 8 to 13, revealed the presence of two bands in the patients, the bigger one corresponding to the wild-type transcript and the shorter one to the mutant transcript, whereas the unaffected member revealed a single band corresponding to the wild-type transcripts. M- Molecular marker (pBR322 x MspI, New England Biolabs). (b) Sequence analysis of the shorter DNA fragment, purified directly from the gel, revealed the skipping of the entire region of exon 10 in every affected relative.

SERCA2 pump truncated in the C-terminal end, containing 413 amino acids rather than the expected 1042 (SERCA2b). The amino acid sequence would be normal until Val395; it would lack the residues encoded by exon 10, which form part of the phosphorylation domain; and the sequence encoded by exon 11, from residue 396 to 413, would be completely abnormal. All mutant SERCA2 splicing variants would lose highly conserved amino acids and motifs hence it would no longer have most of phosphorylation domain, and completely lack the nucleotide-binding and hinge domains, the fifth stalk domain, the transmembrane domains 5 to 10, or 11 in case of SERCA2b.

Therefore, when assessing expression levels of SERCA2, it might be expected to observe a band around 115 kDa, corresponding to the

wild-type pump, and another band of 45 kDa, corresponding to the mutant pump. Nevertheless, western blot results showed no signal of mutant protein in the affected relatives, whereas wild-type SERCA2 presented significantly reduced expression levels, between 40 and 50%, when compared to the healthy individual (Figs. 5a and 5b). Our results showed that the mutant *SERCA2* mRNA escaping to NMD is not translated or, if translated, is very unstable and immediately degraded.

3.5. Proposed pathogenic mechanism

Besides gain of function mutations, autosomal dominant disorders




Fig. 4. All patients showed Sarco/Endoplasmic Reticulum Ca^{2+} ATPase 2 (*SERCA2*) mRNA levels lower than 50% and residual levels of mutant mRNA. Quantitative PCR analysis was performed to quantify the expression levels of (a) both wild-type and mutant transcripts and (b) wild-type transcripts alone. The data are presented as the mean \pm SD of three independent experiments.




Fig. 5. *SERCA2* expression was increasingly reduced in patients when compared with the unaffected relative and the presence of the putative truncated protein was not detected in Darier Disease patients. (a) Wild-type *SERCA2* was significantly reduced in affected individuals. Lymphocytes were lysed with 0.1% SDS and the resulting supernatants were resolved by 7.5% SDS-PAGE loaded with reduced, unheated samples. Anti-*SERCA2* antibody was used for the western blots. After being washed, the same membrane was blotted with anti-beta-actin as the loading control. (b) Putative mutant *SERCA2* (45 kDa) could not be detected by western blot. Blots were incubated with anti-*SERCA2* antibody only in order to detect the putative mutant *SERCA2*. The marker used was NZYColour Protein Marker II (Nzytech). Note: no endogenous control was used because the objective was to detect the putative presence of the mutant *SERCA2* protein.

can also be caused by loss of functions mutations originating either haploinsufficiency or dominant-negative effects. In this specific family where Darier disease segregates, and which is caused by the loss of function c.1287+1G > T or IVS10+1G > T mutation, we could observe that no abnormal variant protein was produced (Fig. 5b); accordingly, a dominant-negative effect may be excluded. So, haploinsufficiency appears to be the most plausible pathogenic mechanism causing this disease condition.

3.6. No genotype-phenotype correlation was found

Since all patients revealed similar levels of *SERCA2* expression, we expected to find additional mutation(s) in the *ATP2A2* gene, which might explain or contribute to the variable phenotypic spectra displayed by the four DD patients. Nevertheless, after screening by Sanger sequencing all exons and respective boundaries, no additional polymorphisms were identified.

4. Discussion

One pivotal point in this study was the identification of the disease-

causing mutation in these family. The c.1287+1G > T or IVS10+1G > T transversion fulfils several criteria for being considered a pathogenic variant, namely: it is located at canonical +1 splice site originating a null variant in the *ATP2A2* gene where loss of function is a known mechanism of disease [18, 19]; it had been previously identified in a Japanese female patient presenting the same phenotype of Darier disease [20].

Another point was to elucidate how c.1287+1G > T affects splicing and the pathogenic mechanism. This transversion immediately reduces the stability of base pairing of the 5' splice site with the complementary region of U1 snRNA [21] and subsequent consequences demonstrate how crucial the highly conserved splice donor site is to the splicing process. The reason why c.1287+1G > T led to exon skipping rather than cryptic splice site usage may rely on potential spliceosome's functional response influencing factors, such as local sequence context of the affected exon-intron junction and vicinities [22]; RNA secondary structure [22]; or open reading frame conservation [22]. The mutant mRNA contains a putative PTC located 74 bp upstream the 3'-most exon-exon junction (exon11-exon12). According to the 50–55 bp rule, a transcript containing a PTC located upstream 50–55 bp from the 3'-most exon-exon junction is immediately recognized by the NMD system [23]. However, herein, the mutant *SERCA2* mRNA is not entirely degraded but the putative

abnormal protein is not detected; therefore, we predict that mutant SERCA2 is too unstable and immediately degraded by proteasomes, or that the translation of mutant mRNA is repressed by another surveillance mechanism [23]. Studies point that translational repression might depend on a putative *cis*-element residing in 3'-UTR, such as DNA transposons [23, 24]. Shen *et al.* revealed that miniature inverted-repeat transposable elements in the 3'-UTRs function as important regulators of translation, therefore these could be potential *cis*-element candidates [24]. Because putative mutant SERCA2 was not detected in the affected relatives, dominant-negative effect by SERCA2 oligomerization is unlikely to occur. Rather, although heterozygous *ATP2A2* knockout mice do not exhibit DD features [8, 25, 26], this study demonstrates that, in these patients, the identified splice-site mutation in *ATP2A2* appears to produce a dominant DD phenotype through haploinsufficiency.

The previous results, when compared with the main dermatological features of patients, strongly suggest that one single normal *ATP2A2* allele is not enough to maintain Ca^{2+} homeostasis in the skin, the organ mostly exposed to outside influence and where SERCA2b is expressed at higher levels.

Because all patients demonstrate similar levels of *ATP2A2* mRNA and protein expression, haploinsufficiency of SERCA2 by itself cannot explain the variable clinical severity observed among affected relatives. Nevertheless, the phenotype of heterozygous individuals becomes more prone to external influences, as it usually occurs in dominant inherited disorders [18]. Herein, we wanted to examine genotype-phenotype relationships by screening all exons and intronic flanking regions of *ATP2A2* gene for additional variants and try to correlate these with the patients' clinical history and different clinical severity. However, no additional polymorphisms were found. Nevertheless, *ATP2A2* contains several introns with extensive size that were not entirely sequenced. Thus, we cannot demonstrate whether additional deep-intronic variants or large insertions/deletions exist within these regions.

Although no genotype-phenotype relationship has been found, we highlight that, not only genetic factors play an important role in phenotypic variability, but also non-genetic factors. SERCA2 pleiotropy, impairment in a SERCA2 epistatic partner, epigenetic changes, or different lifestyles, could play a role in phenotypic variability.

In this two-generation family, some patients have developed non-cutaneous phenotypes that we find relevant to report. Depressive moods and epilepsy have been reported in patient II.1 and patient II.3, respectively. Disruption of intracellular Ca^{2+} homeostasis and function of adhesion molecules has been reported in both abovementioned neuropsychiatric conditions, epilepsy and depressive moods; moreover, it has already been described that the prevalence rates of these conditions are higher in DD patients than in general population [4, 17]. Because the other affected relatives do not show these symptoms, it seems that these may not be a direct consequence of the *ATP2A2* mutation alone. Rather, these phenotypes might need to occur in the presence of environmental factors and genetic variants other than the *ATP2A2* mutation, either from the same or different *loci*.

Renal complications have also been reported in DD patients [27, 28]. Herein we report a case of membranous nephropathy from patient II.1. We cannot conclude whether this disease occurs by chance or the opposite. It is well established, however, that ER stress is one of the major causes of kidney disease [29].

Additionally, a number of ocular features have been previously described in DD patients [30, 31, 32, 33]. We report a case of herpes virus simplex (HSV) infection in the cornea of the left eye of patient I.2 and alert for the relationship between possible impaired adhesion molecules in the corneal epithelium and the increased risk of HSV infection. Patient I.2 has been submitted to two transplants of the affected cornea.

Lastly, we report in patient II.1 a case of chronic middle ear infection due to recurrent skin lesions in the ear, which have damaged the eardrum and reduced hearing capacity of the left ear.

In conclusion, this study identified the disease-causing mutation in this family and contributed to enlarge the worldwide mutational spectrum of DD. This study also confirmed the phenotypic variability of this pathology, namely reporting the presence of neuropsychiatric symptoms, thus highlighting the importance of a wide range of clinical occurrences deserving to be closely monitored.

Declarations

Author contribution statement

Andreia Almeida: Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Maria Lurdes Lobo, Cecília Moura: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.

Isabel Rivera: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

Supplementary content related to this article has been published online at <https://doi.org/10.1016/j.heliyon.2019.e02520>.

References

- [1] A. Hovnanian, Darier's disease: from dyskeratosis to endoplasmic reticulum calcium ATPase deficiency, *Biochem. Biophys. Res. Commun.* 322 (2004) 1237–1344.
- [2] P. Gélébart, V. Martin, J. Enouf, B. Papp, Identification of a new SERCA2 splice variant regulated during monocytic differentiation, *Biochem. Biophys. Res. Commun.* 303 (2003) 676–684.
- [3] M. Savignac, A. Edir, M. Simon, A. Hovnanian, Darier disease: a disease model of impaired calcium homeostasis in the skin, *Biochim. Biophys. Acta Mol. Cell Res.* 1813 (2011) 1111–1117.
- [4] A. Britzolaki, J. Saurine, E. Flaherty, C. Thelen, P.M. Pitychoutis, The SERCA2: a gatekeeper of neuronal calcium homeostasis in the brain, *Cell. Mol. Neurobiol.* 38 (2018) 981–994.
- [5] S. Tavadia, K.S. Authi, M.B. Hodgins, C.S. Munro, Expression of the sarco/endoplasmic reticulum calcium ATPase type 2 and 3 isoforms in normal skin and Darier's disease, *Br. J. Dermatol.* 151 (2004) 440–445.
- [6] T. Strachan, A. Hovnanian, A. Sakuntabhai, V. Ruiz-Perez, S. Carter, N. Jacobsen, S. Burge, S. Monk, M. Smith, C.S. Munro, M. O'Donovan, N. Craddock, R. Kucherlapati, J.L. Rees, M. Owen, G.M. Lathrop, A.P. Monaco, Mutations in *ATP2A2*, encoding a Ca^{2+} pump, cause Darier disease, *Nat. Genet.* 21 (1999) 271–277.
- [7] W. Ahn, M.G. Lee, K.H. Kim, S. Muallem, Multiple effects of SERCA2b mutations associated with Darier's disease, *J. Biol. Chem.* 278 (2003) 20795–20801.
- [8] Y. Wang, A.T. Bruce, C. Tu, K. Ma, L. Zeng, P. Zheng, Y. Liu, Y. Liu, Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes, *J. Cell Sci.* 124 (2011) 3568–3580.
- [9] N. Li, M. Park, S. Xiao, Z. Liu, L.A. Diaz, ER-to-Golgi blockade of nascent desmosomal cadherins in SERCA2-inhibited keratinocytes: implications for Darier's disease, *Traffic* 18 (2017) 232–241.
- [10] A. Celli, D.S. MacKenzie, Y. Zhai, C.L. Tu, D.D. Bikle, W.M. Holleran, Y. Uchida, T.M. Mauro, SERCA2-controlled Ca^{2+} -dependent keratinocyte adhesion and differentiation is mediated via the sphingolipid pathway: a therapeutic target for Darier's disease, *J. Investig. Dermatol.* 132 (2012) 1188–1195.
- [11] I.U.S. Leong, A. Stuckey, T. Ahanian, M. Cederlöf, J.D. Wikstrom, Novel mutations in Darier disease and association to self-reported disease severity, *PLoS One* 12 (2017) 1–15.
- [12] M. Cederlöf, S.E. Bergen, N. Långström, H. Larsson, M. Boman, N. Craddock, P. Östberg, S. Lundström, A. Sjölander, K. Nordlind, M. Landén, P. Lichtenstein, The association between Darier disease, bipolar disorder, and schizophrenia revisited: a population-based family study, *Bipolar Disord.* 17 (2015) 340–344.

- [13] M. Cederlöf, R. Karlsson, H. Larsson, C. Almqvist, P.K.E. Magnusson, K. Nordlind, M. Landén, P. Lichtenstein, Intellectual disability and cognitive ability in Darier disease: Swedish nation-wide study, *Br. J. Dermatol.* 173 (2015) 155–158.
- [14] Q.C. Júnior, D.M. Werebe, H. Vallada, Darier's disease: a new paradigm for genetic studies in psychiatric disorders, *Sao Paulo Med. J.* 118 (2000) 201–203.
- [15] R. Dodiuk-Gad, M. Lerner, Z. Breznitz, E. Cohen-Barak, M. Ziv, A. Shani-Adir, B. Amichai, A. Zlotogorski, S. Shalev, D. Rozenman, Learning disabilities in Darier's disease patients, *J. Eur. Acad. Dermatol. Venereol.* 28 (2014) 314–319.
- [16] K. Gordon-Smith, L.A. Jones, S.M. Burge, C.S. Munro, S. Tavadia, N. Craddock, The neuropsychiatric phenotype in Darier disease, *Br. J. Dermatol.* 163 (2010) 515–522.
- [17] S. Burge, Management of Darier's disease, *Clin. Exp. Dermatol.* 24 (1999) 53–56.
- [18] T. Strachan, A. Read, *Human Molecular Genetics*, fourth ed., Garland Science, 2011.
- [19] S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W.W. Grody, M. Hegde, E. Lyon, E. Spector, K. Voelkerding, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology, *Genet. Med.* 17 (2015) 405–424.
- [20] K. Yoneda, T. Demitsu, Y. Kubota, Novel ATP2A2 mutation in a patient with Darier's disease, *J. Dermatol.* 41 (2014) 349–350.
- [21] M. Krawczak, J. Reiss, D.N. Cooper, The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences, *Hum. Genet.* 90 (1992) 41–54.
- [22] M. Krawczak, N.S.T. Thomas, B. Hundrieser, M. Mort, M. Wittig, J. Hampe, D.N. Cooper, Single base-pair substitutions in exon–intron junctions of human genes: nature, distribution, and consequences for mRNA splicing, *Hum. Mutat.* 28 (2007) 150–158.
- [23] T.Y. Kwon, S.L. Long, N.G. Kim, J.K. Hyun, H.K. Kwi, Y.J. Chwa, M.K. Kyoung, K.K. Yoon, M.P. Sung, K.J. Sung, H. Kim, Selective translational repression of truncated proteins from frameshift mutation-derived mRNAs in tumors, *PLoS Biol.* 5 (2007) 1098–1109.
- [24] J. Shen, J. Liu, K. Xie, F. Xing, F. Xiong, J. Xiao, X. Li, L. Xiong, Translational repression by a miniature inverted-repeat transposable element in the 3' untranslated region, *Nat. Commun.* 8 (2017) 1–10.
- [25] V. Prasad, G.P. Boivin, M.L. Miller, L.H. Liu, C.R. Erwin, B.W. Warner, G.E. Shull, Haploinsufficiency of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca²⁺-ATPase isoform 2 Ca²⁺ pump, predisposes mice to squamous cell tumors via a novel mode of cancer susceptibility, *Cancer Res.* 65 (2005) 8655–8661.
- [26] V. Prasad, J.N. Lorenz, V.M. Lasko, M.L. Nieman, W. Huang, Y. Wang, D.W. Wieczorek, G.E. Shull, SERCA2 haploinsufficiency in a mouse model of darier disease causes a selective predisposition to heart failure, *BioMed Res. Int.* 2015 (2015), 251598, 21 p.
- [27] U. Tursen, E. Erdem, D. Ustunsoy, L. Cinel, G. Ikizoglu, Darier's disease associated with horseshoe kidney, *J. Eur. Acad. Dermatol. Venereol.* 20 (2006) 235–236.
- [28] J. Thomas, B.R. Sindhu, Darier's disease with cystic changes in the kidney, *Int. J. Dermatol.* 53 (2014) 405–406.
- [29] M. Taniguchi, H. Yoshida, Endoplasmic reticulum stress in kidney function and disease, *Curr. Opin. Nephrol. Hypertens.* 24 (2015) 345–350.
- [30] M. Radia, M.J. Gilhooley, C. Panos, C. Cloué, Recurrent presumed herpes simplex keratitis and episcleritis in keratosis follicularis (Darier's disease), *BMJ Case Rep.* 2015 (2015), bcr2015210772. Published 2015 July 16.
- [31] H.J. Blackman, M.M. Rodrigues, G.L. Peck, Corneal epithelial lesions in keratosis follicularis (Darier's Disease), *Ophthalmology* 87 (1980) 931–943.
- [32] D. Mathews, L.P. Perera, M.L.D. Irion, F. Carley, Darier Disease: beware the cyst that smells, *Am. Soc. Ophthalmic Plast. Reconstr. Surg.* 26 (2010) 206–207.
- [33] J. Mielke, M. Grüb, D. Besch, T. Schlote, Recurrent corneal ulcerations with perforation in keratosis follicularis (Darier-White disease), *Br. J. Ophthalmol.* 86 (2002) 1192–1193.